Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$0.00$0.00— vs Q3 2021 Net Income-$77.69K-$77.69KN/M vs Q3 2021 EPS Diluted$0.00$0.00— vs Q3 2021 Operating Income-$69,987N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
derived
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end